biostudies-literaturePrice JNational Institute On AgingCTSANCATS NIH HHSNational Institute on Alcohol Abuse and AlcoholismNational Institute of Diabetes and Digestive and Kidney DiseasesAmerican College of GastroenterologyNIAID NIH HHSNHLBI NIH HHSNational Heart, Lung, and Blood InstituteNIMH NIH HHSNational Institutes of Health, Office of AIDS ResearchNational Institute on Deafness and Other Communication DisordersEunice Kennedy Shriver National Institute Of Child Health &amp; Human DevelopmentNational Institutes of HealthNational Institute Of Neurological Disorders And StrokeNational Institute on Minority Health and Health DisparitiesNational Institute of Allergy and Infectious DiseasesNational Institute Of Dental &amp; Craniofacial ResearchNIDDK NIH HHSCTSINational Cancer InstituteNational Institute Of Nursing ResearchNational Institute On Drug AbuseNational Institute Of Mental Healthe055706https://www.ebi.ac.uk/biostudies/studies/S-EPMC8991036biostudies-literatureUnknown12(4)<h4>Purpose</h4>The Liver Disease and Reproductive Ageing (LIVRA) study leverages the infrastructure of the decades-long multicentre prospective Women's Interagency HIV Study (WIHS) to examine the contributions of HIV, hepatitis C virus (HCV) and ageing to liver disease progression in women.<h4>Participants</h4>From 2013 to 2018, LIVRA enrolled 1576 participants (77 HCV-seropositive only, 248 HIV/HCV-seropositive, 868 HIV-seropositive only and 383 HIV/HCV-seronegative) who underwent vibration controlled transient elastography (VCTE). A VCTE quality assurance programme was established to ensure consistency and accuracy for longitudinal assessment of steatosis (fatty liver) via the controlled attenuation parameter (CAP) and fibrosis via liver stiffness (LS). Demographic, lifestyle factors, aBMJ openMultisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV.PMC8991036U01-HL1462415R01DK109823U01-HL146240UL1 TR001881U01-HL146203U01-HL146202U01 HL146205U01 HL146204U01-HL146205U01 HL146203U01-HL146204U01-HL146242U01-HL146201U01-HL146245U01 HL146208U01 HL146242UL1-TR003098U01 HL146241U01 HL146240U01 HL146202U01 HL146245U01 HL146201K24 AI 108516P30-MH-116867U01-HL146194P30 AI027767P30 AI073961U01 AI031834U01-HL146193U01 AI034989U01-HL146192UL1 TR000004P30-AI-050409R01 DK109823P30-AI-027767U01 HL146194U01 HL146193U01 HL146192P30 AI050410K24 AI108516UL1-TR000004P30-AI-050410P30 MH116867UL1 TR003098UL1-TR001881P30 AI050409U01-HL146333U01 HL146333U01-HL146208P30-AI-073961Price JOfotokun ISharma AKuniholm MHFischl MPlankey MFrench ALMa YKonkle-Parker DAdimora AGolub ETTien PCfalseMultisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV.<h4>Purpose</h4>The Liver Disease and Reproductive Ageing (LIVRA) study leverages the infrastructure of the decades-long multicentre prospective Women's Interagency HIV Study (WIHS) to examine the contributions of HIV, hepatitis C virus (HCV) and ageing to liver disease progression in women.<h4>Participants</h4>From 2013 to 2018, LIVRA enrolled 1576 participants (77 HCV-seropositive only, 248 HIV/HCV-seropositive, 868 HIV-seropositive only and 383 HIV/HCV-seronegative) who underwent vibration controlled transient elastography (VCTE). A VCTE quality assurance programme was established to ensure consistency and accuracy for longitudinal assessment of steatosis (fatty liver) via the controlled attenuation parameter (CAP) and fibrosis via liver stiffness (LS). Demographic, lifestyle factors, a2022-01-01T00:00:00Z2022 Apr2026-06-18T05:04:47.387Z2025-04-06T10:57:51.428ZS-EPMC89910363539331010.1136/bmjopen-2021-055706